Non-alcoholic fatty liver and the gut microbiota

Molecular Metabolism

Volumn 5, Issue 9, 2016, Pages 782-794

  Bashiardes, Stavros ^a   Shapiro, Hagit ^a   Rozin, Shachar ^a   Shibolet, Oren ^b,c   Elinav, Eran ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Liver; Microbiome; NAFLD; NASH

Indexed keywords

BACITRACIN; BILE ACID; LIPOPOLYSACCHARIDE; NEOMYCIN; PROBIOTIC AGENT; RNA 16S; SHORT CHAIN FATTY ACID; STREPTOMYCIN;

ACTINOBACTERIA; ARTICLE; BACTEROIDETES; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE COURSE; DYSBIOSIS; ENTEROPATHY; FIRMICUTES; GENE SEQUENCE; HOST PATHOGEN INTERACTION; HUMAN; INTESTINE FLORA; LIFESTYLE MODIFICATION; MICROBIAL COLONIZATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEOBACTERIA;

EID: 84977672194     PISSN: 22128778     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmet.2016.06.003     Document Type: Article

References (139)

1. [1] Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L., Wymer, M., Global epidemiology of non-alcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence and outcomes. Hepatology, Dec 28 2015.
2. [2] Rinella, M.E., Nonalcoholic fatty liver disease: a systematic review. Journal of the American Medical Association 313:22 (Jun 9 2015), 2263–2273.
3. [3] Das, K., Das, K., Mukherjee, P.S., Ghosh, A., Ghosh, S., Mridha, A.R., et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology 51:5 (May 2010), 1593–1602.
4. [4] Ampuero, J., Ranchal, I., Gallego-Duran, R., Pareja, M.J., Del Campo, J.A., Pastor-Ramirez, H., et al. Oxidized LDL antibodies/HDL-c ratio is linked to advanced disease in NAFLD lean patients. Journal of Gastroenterology and Hepatology, Mar 6 2016.
5. [5] Corey, K.E., Rinella, M.E., Medical and surgical treatment options for nonalcoholic steatohepatitis. Digestive Diseases and Sciences 61:5 (May 2016), 1387–1397.
6. [6] Lam, B., Younossi, Z.M., Treatment options for nonalcoholic fatty liver disease. Therapeutic Advances in Gastroenterology 3:2 (Mar 2010), 121–137.
7. [7] Smallwood, T., Allayee, H., Bennett, B.J., Choline metabolites: gene by diet interactions. Current Opinion in Lipidology 27:1 (Feb 2016), 33–39.
8. [8] Al Rajabi, A., Castro, G.S., da Silva, R.P., Nelson, R.C., Thiesen, A., Vannucchi, H., et al. Choline supplementation protects against liver damage by normalizing cholesterol metabolism in Pemt/Ldlr knockout mice fed a high-fat diet. Journal of Nutrition 144:3 (Mar 2014), 252–257.
9. [9] Collison, K.S., Saleh, S.M., Bakheet, R.H., Al-Rabiah, R.K., Inglis, A.L., Makhoul, N.J., et al. Diabetes of the liver: the link between nonalcoholic fatty liver disease and HFCS-55. Obesity (Silver Spring) 17:11 (Nov 2009), 2003–2013.
10. [10] Veena, J., Muragundla, A., Sidgiddi, S., Subramaniam, S., Non-alcoholic fatty liver disease: need for a balanced nutritional source. British Journal of Nutrition 112:11 (Dec 14 2014), 1858–1872.
11. [11] Smagris, E., BasuRay, S., Li, J., Huang, Y., Lai, K.M., Gromada, J., et al. Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology 61:1 (Jan 2015), 108–118.
12. [12] Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L.A., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nature Genetics 40:12 (Dec 2008), 1461–1465.
13. [13] Sookoian, S., Pirola, C.J., Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 53:6 (Jun 2011), 1883–1894.
14. [14] Walkey, C.J., Yu, L., Agellon, L.B., Vance, D.E., Biochemical and evolutionary significance of phospholipid methylation. Journal of Biological Chemistry 273:42 (Oct 16 1998), 27043–27046.
15. [15] Waite, K.A., Cabilio, N.R., Vance, D.E., Choline deficiency-induced liver damage is reversible in Pemt(-/-) mice. Journal of Nutrition 132:1 (Jan 2002), 68–71.
16. [16] Song, J., da Costa, K.A., Fischer, L.M., Kohlmeier, M., Kwock, L., Wang, S., et al. Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD). FASEB Journal 19:10 (Aug 2005), 1266–1271.
17. [17] Lander, E.S., Linton, L.M., Birren, B., Nusbaum, C., Zody, M.C., Baldwin, J., et al. Initial sequencing and analysis of the human genome. Nature 409:6822 (Feb 15 2001), 860–921.
18. [18] Relman, D.A., Falkow, S., The meaning and impact of the human genome sequence for microbiology. Trends in Microbiology 9:5 (May 2001), 206–208.
19. [19] Rawls, J.F., Mahowald, M.A., Ley, R.E., Gordon, J.I., Reciprocal gut microbiota transplants from zebrafish and mice to germ-free recipients reveal host habitat selection. Cell 127:2 (Oct 20 2006), 423–433.
20. [20] Backhed, F., Manchester, J.K., Semenkovich, C.F., Gordon, J.I., Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proceedings of the National Academy of Sciences of the United States of America 104:3 (Jan 16 2007), 979–984.
21. [21] Turnbaugh, P.J., Ley, R.E., Mahowald, M.A., Magrini, V., Mardis, E.R., Gordon, J.I., An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444:7122 (Dec 21 2006), 1027–1031.
22. [22] Flint, H.J., Scott, K.P., Duncan, S.H., Louis, P., Forano, E., Microbial degradation of complex carbohydrates in the gut. Gut Microbes 3:4 (Jul–Aug 2012), 289–306.
23. [23] Kamada, N., Chen, G.Y., Inohara, N., Nunez, G., Control of pathogens and pathobionts by the gut microbiota. Nature Immunology 14:7 (Jul 2013), 685–690.
24. [24] Kau, A.L., Ahern, P.P., Griffin, N.W., Goodman, A.L., Gordon, J.I., Human nutrition, the gut microbiome and the immune system. Nature 474:7351 (Jun 16 2011), 327–336.
25. [25] Yamamoto, M., Yamaguchi, R., Munakata, K., Takashima, K., Nishiyama, M., Hioki, K., et al. A microarray analysis of gnotobiotic mice indicating that microbial exposure during the neonatal period plays an essential role in immune system development. BMC Genomics, 13, 2012, 335.
26. [26] Human Microbiome Project Consortium, Structure, function and diversity of the healthy human microbiome. Nature 486:7402 (Jun 14 2012), 207–214.
27. [27] Turnbaugh, P.J., Hamady, M., Yatsunenko, T., Cantarel, B.L., Duncan, A., Ley, R.E., et al. A core gut microbiome in obese and lean twins. Nature 457:7228 (Jan 22 2009), 480–484.
28. [28] Arumugam, M., Raes, J., Pelletier, E., Le Paslier, D., Yamada, T., Mende, D.R., et al. Enterotypes of the human gut microbiome. Nature 473:7346 (May 12 2011), 174–180.
29. [29] Frank, D.N., St Amand, A.L., Feldman, R.A., Boedeker, E.C., Harpaz, N., Pace, N.R., Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proceedings of the National Academy of Sciences of the United States of America 104:34 (Aug 21 2007), 13780–13785.
30. [30] Larsen, N., Vogensen, F.K., van den Berg, F.W., Nielsen, D.S., Andreasen, A.S., Pedersen, B.K., et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PloS One, 5(2), 2010, e9085.
31. [31] Wang, F., Kaplan, J.L., Gold, B.D., Bhasin, M.K., Ward, N.L., Kellermayer, R., et al. Detecting microbial dysbiosis associated with pediatric Crohn disease despite the high variability of the gut microbiota. Cell Reports 14:4 (Feb 2 2016), 945–955.
32. [32] Wang, Z., Klipfell, E., Bennett, B.J., Koeth, R., Levison, B.S., Dugar, B., et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472:7341 (Apr 7 2011), 57–63.
33. [33] Brown, K., Godovannyi, A., Ma, C., Zhang, Y., Ahmadi-Vand, Z., Dai, C., et al. Prolonged antibiotic treatment induces a diabetogenic intestinal microbiome that accelerates diabetes in NOD mice. ISME Journal 10:2 (Feb 2016), 321–332.
34. [34] Reikvam, D.H., Erofeev, A., Sandvik, A., Grcic, V., Jahnsen, F.L., Gaustad, P., et al. Depletion of murine intestinal microbiota: effects on gut mucosa and epithelial gene expression. PloS One, 6(3), 2011, e17996.
35. [35] Ridaura, V.K., Faith, J.J., Rey, F.E., Cheng, J., Duncan, A.E., Kau, A.L., et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science, 341(6150), Sep 6 2013, 1241214.
36. [36] Backhed, F., Ding, H., Wang, T., Hooper, L.V., Koh, G.Y., Nagy, A., et al. The gut microbiota as an environmental factor that regulates fat storage. Proceedings of the National Academy of Sciences of the United States of America 101:44 (Nov 2 2004), 15718–15723.
37. [37] Caesar, R., Tremaroli, V., Kovatcheva-Datchary, P., Cani, P.D., Backhed, F., Crosstalk between gut microbiota and dietary lipids aggravates WAT inflammation through TLR signaling. Cell Metabolism 22:4 (Oct 6 2015), 658–668.
38. [38] Ley, R.E., Turnbaugh, P.J., Klein, S., Gordon, J.I., Microbial ecology: human gut microbes associated with obesity. Nature 444:7122 (Dec 21 2006), 1022–1023.
39. [39] Schwiertz, A., Taras, D., Schafer, K., Beijer, S., Bos, N.A., Donus, C., et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring) 18:1 (Jan 2010), 190–195.
40. [40] Zhang, H., DiBaise, J.K., Zuccolo, A., Kudrna, D., Braidotti, M., Yu, Y., et al. Human gut microbiota in obesity and after gastric bypass. Proceedings of the National Academy of Sciences of the United States of America 106:7 (Feb 17 2009), 2365–2370.
41. [41] Abdel-Misih, S.R., Bloomston, M., Liver anatomy. Surgical Clinics of North America 90:4 (Aug 2010), 643–653.
42. [42] Abu-Shanab, A., Quigley, E.M., The role of the gut microbiota in nonalcoholic fatty liver disease. Nature Reviews Gastroenterology & Hepatology 7:12 (Dec 2010), 691–701.
43. [43] Drenick, E.J., Fisler, J., Johnson, D., Hepatic steatosis after intestinal bypass – prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition. Gastroenterology 82:3 (Mar 1982), 535–548.
44. [44] Wigg, A.J., Roberts-Thomson, I.C., Dymock, R.B., McCarthy, P.J., Grose, R.H., Cummins, A.G., The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 48:2 (Feb 2001), 206–211.
45. [45] Rabot, S., Membrez, M., Bruneau, A., Gerard, P., Harach, T., Moser, M., et al. Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism. FASEB Journal 24:12 (Dec 2010), 4948–4959.
46. [46] Le Roy, T., Llopis, M., Lepage, P., Bruneau, A., Rabot, S., Bevilacqua, C., et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 62:12 (Dec 2013), 1787–1794.
47. [47] Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W.Z., Strowig, T., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482:7384 (Feb 9 2012), 179–185.
48. [48] Zeng, H., Liu, J., Jackson, M.I., Zhao, F.Q., Yan, L., Combs, G.F. Jr., Fatty liver accompanies an increase in lactobacillus species in the hind gut of C57BL/6 mice fed a high-fat diet. Journal of Nutrition 143:5 (May 2013), 627–631.
49. [49] Wu, G.D., Chen, J., Hoffmann, C., Bittinger, K., Chen, Y.Y., Keilbaugh, S.A., et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 334:6052 (Oct 7 2011), 105–108.
50. [50] Zeevi, D., Korem, T., Zmora, N., Israeli, D., Rothschild, D., Weinberger, A., et al. Personalized nutrition by prediction of glycemic responses. Cell 163:5 (Nov 19 2015), 1079–1094.
51. [51] Schnabl, B., Brenner, D.A., Interactions between the intestinal microbiome and liver diseases. Gastroenterology 146:6 (May 2014), 1513–1524.
52. [52] Michail, S., Lin, M., Frey, M.R., Fanter, R., Paliy, O., Hilbush, B., et al. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiology Ecology 91:2 (Feb 2015), 1–9.
53. [53] Spencer, M.D., Hamp, T.J., Reid, R.W., Fischer, L.M., Zeisel, S.H., Fodor, A.A., Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology 140:3 (Mar 2011), 976–986.
54. [54] Jiang, W., Wu, N., Wang, X., Chi, Y., Zhang, Y., Qiu, X., et al. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Scientific Reports, 5, 2015, 8096.
55. [55] Raman, M., Ahmed, I., Gillevet, P.M., Probert, C.S., Ratcliffe, N.M., Smith, S., et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clinical Gastroenterology and Hepatology 11:7 (Jul 2013), 868–875 e861–863.
56. [56] Zhu, L., Baker, S.S., Gill, C., Liu, W., Alkhouri, R., Baker, R.D., et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 57:2 (Feb 2013), 601–609.
57. [57] Mouzaki, M., Comelli, E.M., Arendt, B.M., Bonengel, J., Fung, S.K., Fischer, S.E., et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 58:1 (Jul 2013), 120–127.
58. [58] Wong, V.W., Wong, G.L., Chan, H.Y., Yeung, D.K., Chan, R.S., Chim, A.M., et al. Bacterial endotoxin and non-alcoholic fatty liver disease in the general population: a prospective cohort study. Alimentary Pharmacology & Therapeutics 42:6 (Sep 2015), 731–740.
59. [59] Boursier, J., Mueller, O., Barret, M., Machado, M., Fizanne, L., Araujo-Perez, F., et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 63:3 (Mar 2016), 764–775.
60. [60] Langille, M.G., Zaneveld, J., Caporaso, J.G., McDonald, D., Knights, D., Reyes, J.A., et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nature Biotechnology 31:9 (Sep 2013), 814–821.
61. [61] Klatt, N.R., Funderburg, N.T., Brenchley, J.M., Microbial translocation, immune activation, and HIV disease. Trends in Microbiology 21:1 (Jan 2013), 6–13.
62. [62] Peterson, L.W., Artis, D., Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nature Reviews. Immunology 14:3 (Mar 2014), 141–153.
63. [63] Brenchley, J.M., Douek, D.C., HIV infection and the gastrointestinal immune system. Mucosal Immunology 1:1 (Jan 2008), 23–30.
64. [64] Honda, K., Littman, D.R., The microbiome in infectious disease and inflammation. Annual Review of Immunology 30 (2012), 759–795.
65. [65] Miele, L., Valenza, V., La Torre, G., Montalto, M., Cammarota, G., Ricci, R., et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49:6 (Jun 2009), 1877–1887.
66. [66] Giorgio, V., Miele, L., Principessa, L., Ferretti, F., Villa, M.P., Negro, V., et al. Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity. Digestive and Liver Disease 46:6 (Jun 2014), 556–560.
67. [67] Everard, A., Cani, P.D., Diabetes, obesity and gut microbiota. Best Practice & Research. Clinical Gastroenterology 27:1 (Feb 2013), 73–83.
68. [68] Tremaroli, V., Backhed, F., Functional interactions between the gut microbiota and host metabolism. Nature 489:7415 (Sep 13 2012), 242–249.
69. [69] Brun, P., Castagliuolo, I., Di Leo, V., Buda, A., Pinzani, M., Palu, G., et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. American Journal of Physiology. Gastrointestinal and Liver Physiology 292:2 (Feb 2007), G518–G525.
70. [70] Llorente, C., Schnabl, B., The gut microbiota and liver disease. Cellular and Molecular Gastroenterology and Hepatology 1:3 (May 1 2015), 275–284.
71. [71] Gabele, E., Dostert, K., Hofmann, C., Wiest, R., Scholmerich, J., Hellerbrand, C., et al. DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. Journal of Hepatology 55:6 (Dec 2011), 1391–1399.
72. [72] Luther, J., Garber, J.J., Khalili, H., Dave, M., Bale, S.S., Jindal, R., et al. Hepatic injury in nonalcoholic steatohepatitis contributes to altered intestinal permeability. Cellular and Molecular Gastroenterology and Hepatology 1:2 (Mar 2015), 222–232.
73. [73] Miura, K., Ohnishi, H., Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World Journal of Gastroenterology 20:23 (Jun 21 2014), 7381–7391.
74. [74] Nakamoto, N., Kanai, T., Role of toll-like receptors in immune activation and tolerance in the liver. Frontiers in Immunology, 5, 2014, 221.
75. [75] Csak, T., Ganz, M., Pespisa, J., Kodys, K., Dolganiuc, A., Szabo, G., Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology 54:1 (Jul 2011), 133–144.
76. [76] Dixon, L.J., Berk, M., Thapaliya, S., Papouchado, B.G., Feldstein, A.E., Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis. Laboratory Investigation 92:5 (May 2012), 713–723.
77. [77] Yang, G., Lee, H.E., Lee, J.Y., A pharmacological inhibitor of NLRP3 inflammasome prevents non-alcoholic fatty liver disease in a mouse model induced by high fat diet. Scientific Reports, 6, 2016, 24399.
78. [78] Shapiro, H., Thaiss, C.A., Levy, M., Elinav, E., The cross talk between microbiota and the immune system: metabolites take center stage. Current Opinion in Immunology 30 (Oct 2014), 54–62.
79. [79] Rooks, M.G., Garrett, W.S., Gut microbiota, metabolites and host immunity. Nature Reviews. Immunology 16:6 (May 27 2016), 341–352.
80. [80] Levy, M., Thaiss, C.A., Zeevi, D., Dohnalova, L., Zilberman-Schapira, G., Mahdi, J.A., et al. Microbiota-modulated metabolites shape the intestinal microenvironment by regulating NLRP6 inflammasome signaling. Cell 163:6 (Dec 3 2015), 1428–1443.
81. [81] Zhu, W., Gregory, J.C., Org, E., Buffa, J.A., Gupta, N., Wang, Z., et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell 165:1 (Mar 24 2016), 111–124.
82. [82] Raetz, C.R., Whitfield, C., Lipopolysaccharide endotoxins. Annual Review of Biochemistry 71 (2002), 635–700.
83. [83] Dixon, L.J., Barnes, M., Tang, H., Pritchard, M.T., Nagy, L.E., Kupffer cells in the liver. Comprehensive Physiology 3:2 (Apr 2013), 785–797.
84. [84] Asehnoune, K., Strassheim, D., Mitra, S., Kim, J.Y., Abraham, E., Involvement of reactive oxygen species in Toll-like receptor 4-dependent activation of NF-kappa B. Journal of Immunology 172:4 (Feb 15 2004), 2522–2529.
85. [85] Lu, Y.C., Yeh, W.C., Ohashi, P.S., LPS/TLR4 signal transduction pathway. Cytokine 42:2 (May 2008), 145–151.
86. [86] Cani, P.D., Amar, J., Iglesias, M.A., Poggi, M., Knauf, C., Bastelica, D., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56:7 (Jul 2007), 1761–1772.
87. [87] Rivera, C.A., Adegboyega, P., van Rooijen, N., Tagalicud, A., Allman, M., Wallace, M., Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. Journal of Hepatology 47:4 (Oct 2007), 571–579.
88. [88] Cani, P.D., Bibiloni, R., Knauf, C., Waget, A., Neyrinck, A.M., Delzenne, N.M., et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57:6 (Jun 2008), 1470–1481.
89. [89] Harte, A.L., da Silva, N.F., Creely, S.J., McGee, K.C., Billyard, T., Youssef-Elabd, E.M., et al. Elevated endotoxin levels in non-alcoholic fatty liver disease. Journal of Inflammation (London), 7, 2010, 15.
90. [90] Mehta, N.N., McGillicuddy, F.C., Anderson, P.D., Hinkle, C.C., Shah, R., Pruscino, L., et al. Experimental endotoxemia induces adipose inflammation and insulin resistance in humans. Diabetes 59:1 (Jan 2010), 172–181.
91. [91] Bach Knudsen, K.E., Microbial degradation of whole-grain complex carbohydrates and impact on short-chain fatty acids and health. Advances in Nutrition 6:2 (Mar 2015), 206–213.
92. [92] De Vadder, F., Kovatcheva-Datchary, P., Goncalves, D., Vinera, J., Zitoun, C., Duchampt, A., et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 156:1–2 (Jan 16 2014), 84–96.
93. [93] den Besten, G., van Eunen, K., Groen, A.K., Venema, K., Reijngoud, D.J., Bakker, B.M., The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. Journal of Lipid Research 54:9 (Sep 2013), 2325–2340.
94. [94] Puertollano, E., Kolida, S., Yaqoob, P., Biological significance of short-chain fatty acid metabolism by the intestinal microbiome. Current Opinion in Clinical Nutrition & Metabolic Care 17:2 (Mar 2014), 139–144.
95. [95] Kimura, I., Ozawa, K., Inoue, D., Imamura, T., Kimura, K., Maeda, T., et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nature Communications, 4, 2013, 1829.
96. [96] Maslowski, K.M., Vieira, A.T., Ng, A., Kranich, J., Sierro, F., Yu, D., et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 461:7268 (Oct 29 2009), 1282–1286.
97. [97] Ridlon, J.M., Kang, D.J., Hylemon, P.B., Bile salt biotransformations by human intestinal bacteria. Journal of Lipid Research 47:2 (Feb 2006), 241–259.
98. [98] Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., Schoonjans, K., Targeting bile-acid signalling for metabolic diseases. Nature Reviews Drug Discovery 7:8 (Aug 2008), 678–693.
99. [99] Chiang, J.Y., Bile acids: regulation of synthesis. Journal of Lipid Research 50:10 (Oct 2009), 1955–1966.
100. [100] Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metabolism 10:3 (Sep 2009), 167–177.
101. [101] Claus, S.P., Tsang, T.M., Wang, Y., Cloarec, O., Skordi, E., Martin, F.P., et al. Systemic multicompartmental effects of the gut microbiome on mouse metabolic phenotypes. Molecular Systems Biology, 4, 2008, 219.
102. [102] Kuribayashi, H., Miyata, M., Yamakawa, H., Yoshinari, K., Yamazoe, Y., Enterobacteria-mediated deconjugation of taurocholic acid enhances ileal farnesoid X receptor signaling. European Journal of Pharmacology 697:1–3 (Dec 15 2012), 132–138.
103. [103] Sayin, S.I., Wahlstrom, A., Felin, J., Jantti, S., Marschall, H.U., Bamberg, K., et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metabolism 17:2 (Feb 5 2013), 225–235.
104. [104] Swann, J.R., Want, E.J., Geier, F.M., Spagou, K., Wilson, I.D., Sidaway, J.E., et al. Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. Proceedings of the National Academy of Sciences of the United States of America 108:Suppl 1 (Mar 15 2011), 4523–4530.
105. [105] Lee, F.Y., Lee, H., Hubbert, M.L., Edwards, P.A., Zhang, Y., FXR, a multipurpose nuclear receptor. Trends in Biochemical Sciences 31:10 (Oct 2006), 572–580.
106. [106] Yuan, L., Bambha, K., Bile acid receptors and nonalcoholic fatty liver disease. World Journal of Hepatology 7:28 (Dec 8 2015), 2811–2818.
107. [107] Huang, W., Ma, K., Zhang, J., Qatanani, M., Cuvillier, J., Liu, J., et al. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science 312:5771 (Apr 14 2006), 233–236.
108. [108] Cipriani, S., Mencarelli, A., Palladino, G., Fiorucci, S., FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. Journal of Lipid Research 51:4 (Apr 2010), 771–784.
109. [109] de Aguiar Vallim, T.Q., Tarling, E.J., Edwards, P.A., Pleiotropic roles of bile acids in metabolism. Cell Metabolism 17:5 (May 7 2013), 657–669.
110. [110] Neuschwander-Tetri, B.A., Loomba, R., Sanyal, A.J., Lavine, J.E., Van Natta, M.L., Abdelmalek, M.F., et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385:9972 (Mar 14 2015), 956–965.
111. [111] Cariou, B., The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis. Diabetes & Metabolism 34:6 Pt 2 (Dec 2008), 685–691.
112. [112] Prawitt, J., Abdelkarim, M., Stroeve, J.H., Popescu, I., Duez, H., Velagapudi, V.R., et al. Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes 60:7 (Jul 2011), 1861–1871.
113. [113] Sinal, C.J., Tohkin, M., Miyata, M., Ward, J.M., Lambert, G., Gonzalez, F.J., Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102:6 (Sep 15 2000), 731–744.
114. [114] Zhang, Y., Lee, F.Y., Barrera, G., Lee, H., Vales, C., Gonzalez, F.J., et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proceedings of the National Academy of Sciences of the United States of America 103:4 (Jan 24 2006), 1006–1011.
115. [115] Watanabe, M., Horai, Y., Houten, S.M., Morimoto, K., Sugizaki, T., Arita, E., et al. Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure. Journal of Biological Chemistry 286:30 (Jul 29 2011), 26913–26920.
116. [116] Houten, S.M., Volle, D.H., Cummins, C.L., Mangelsdorf, D.J., Auwerx, J., In vivo imaging of farnesoid X receptor activity reveals the ileum as the primary bile acid signaling tissue. Molecular Endocrinology 21:6 (Jun 2007), 1312–1323.
117. [117] Jiang, C., Xie, C., Lv, Y., Li, J., Krausz, K.W., Shi, J., et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nature Communications, 6, 2015, 10166.
118. [118] Jiang, C., Xie, C., Li, F., Zhang, L., Nichols, R.G., Krausz, K.W., et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. Journal of Clinical Investigation 125:1 (Jan 2015), 386–402.
119. [119] Fang, S., Suh, J.M., Reilly, S.M., Yu, E., Osborn, O., Lackey, D., et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nature Medicine 21:2 (Feb 2015), 159–165.
120. [120] Ryan, K.K., Tremaroli, V., Clemmensen, C., Kovatcheva-Datchary, P., Myronovych, A., Karns, R., et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 509:7499 (May 8 2014), 183–188.
121. [121] Mouzaki, M., Wang, A.Y., Bandsma, R., Comelli, E.M., Arendt, B.M., Zhang, L., et al. Bile acids and dysbiosis in non-alcoholic fatty liver disease. PloS One, 11(5), 2016, e0151829.
122. [122] Volynets, V., Kuper, M.A., Strahl, S., Maier, I.B., Spruss, A., Wagnerberger, S., et al. Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD). Digestive Diseases and Sciences 57:7 (Jul 2012), 1932–1941.
123. [123] Yang, M., Gong, S., Ye, S.Q., Lyman, B., Geng, L., Chen, P., et al. Non-alcoholic fatty liver disease in children: focus on nutritional interventions. Nutrients 6:11 (Nov 2014), 4691–4705.
124. [124] Chalasani, N., Younossi, Z., Lavine, J.E., Diehl, A.M., Brunt, E.M., Cusi, K., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55:6 (Jun 2012), 2005–2023.
125. [125] Eslamparast, T., Eghtesad, S., Poustchi, H., Hekmatdoost, A., Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease. World Journal of Hepatology 7:2 (Feb 27 2015), 204–212.
126. [126] Dethlefsen, L., Huse, S., Sogin, M.L., Relman, D.A., The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biology, 6(11), Nov 18 2008, e280.
127. [127] Dethlefsen, L., Relman, D.A., Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proceedings of the National Academy of Sciences of the United States of America 108:Suppl 1 (Mar 15 2011), 4554–4561.
128. [128] Bergheim, I., Weber, S., Vos, M., Kramer, S., Volynets, V., Kaserouni, S., et al. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. Journal of Hepatology 48:6 (Jun 2008), 983–992.
129. [129] Vos, M.B., Lavine, J.E., Dietary fructose in nonalcoholic fatty liver disease. Hepatology 57:6 (Jun 2013), 2525–2531.
130. [130] Madrid, A.M., Hurtado, C., Venegas, M., Cumsille, F., Defilippi, C., Long-term treatment with cisapride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function. American Journal of Gastroenterology 96:4 (Apr 2001), 1251–1255.
131. [131] Soza, A., Riquelme, A., GonzÁlez, R., Alvarez, M., PÉrez-ayuso, R.M., Glasinovic, J.C., et al. Increased orocecal transit time in patients with nonalcoholic fatty liver disease. Digestive Diseases and Sciences 50:6 (2005), 1136–1140.
132. [132] Gareau, M.G., Sherman, P.M., Walker, W.A., Probiotics and the gut microbiota in intestinal health and disease. Nature Reviews Gastroenterology & Hepatology 7:9 (Sep 2010), 503–514.
133. [133] Paolella, G., Mandato, C., Pierri, L., Poeta, M., Di Stasi, M., Vajro, P., Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease. World Journal of Gastroenterology 20:42 (Nov 14 2014), 15518–15531.
134. [134] Loguercio, C., De Simone, T., Federico, A., Terracciano, F., Tuccillo, C., Di Chicco, M., et al. Gut-liver axis: a new point of attack to treat chronic liver damage?. American Journal of Gastroenterology 97:8 (Aug 2002), 2144–2146.
135. [135] Li, Z., Yang, S., Lin, H., Huang, J., Watkins, P.A., Moser, A.B., et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37:2 (Feb 2003), 343–350.
136. [136] Wong, V.W., Tse, C.H., Lam, T.T., Wong, G.L., Chim, A.M., Chu, W.C., et al. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis – a longitudinal study. PloS One, 8(4), 2013, e62885.
137. [137] Gao, X., Zhu, Y., Wen, Y., Liu, G., Wan, C., Efficacy of probiotics in nonalcoholic fatty liver disease in adult and children: a meta-analysis of randomized controlled trials. Hepatology Research, Feb 11 2016.
138. [138] Ma, Y.Y., Li, L., Yu, C.H., Shen, Z., Chen, L.H., Li, Y.M., Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World Journal of Gastroenterology 19:40 (Oct 28 2013), 6911–6918.
139. [139] Del Chierico, F., Nobili, V., Vernocchi, P., Russo, A., De Stefanis, C., Gnani, D., et al. Gut microbiota profiling of pediatric NAFLD and obese patients unveiled by an integrated meta-omics based approach. Hepatology, Mar 29 2016.